Genethon and Hansa Initiate Phase 2 Trial of imlifidase as a Pre-Treatment to GNT-0003 in Severe Crigler-Najjar Syndrome

Source :: Entertainment Close-up. December 17, 2024
Publication Year :: 2024
Abstract: Hansa Biopharma and Genethon, a company focusing on gene therapy research and development for rare genetic diseases, reported initiation of GNT-018-IDES, a Phase 2 trial in patients with Crigler-Najjar syndrome [...]

Subjects :: Genethon -- Product development
Biological products industry -- Product development
Medical research
Medicine, Experimental
Clinical trials
Genetic vectors
Immunoglobulin G
Industrial research
Research and development
Arts and entertainment industries

Tools